SPTX earnings analysis
What we found in SPTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Seaport remains a pre-revenue clinical-stage company, reporting Q2 revenue of $0 and a GAAP loss per share of $1.78, versus a $15.1 million net loss in the prior-year quarter. The quarterly loss expanded to $62.6 million, largely reflecting a $36.0 million IPO-related non-cash stock-compensation charge and higher clinical R&D, while operating cash use was $46.3 million for the first half. The $427.3 million liquidity balance provides a stated runway into 2029, but investment performance remains dependent on clinical readouts beginning in 2H 2026 and BUOY-1 in 1H 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- IPO supports runway into 2029
- Cash, cash equivalents and investments were $427.3 million at June 30, 2026 following $238.4 million of net IPO proceeds, which management believes funds operations and capital expenditures into 2029.
- Near-term clinical catalysts remain on track
- GlyphAllo's Phase 2b BUOY-1 trial remains underway, with topline data anticipated in the first half of 2027; a Phase 1 driving-simulation study is expected to report topline data in the second half of 2026.
- GlyphAgo pharmacokinetic data were favorable
- GlyphAgo Phase 1 data showed a 6.8-fold bioavailability increase versus oral agomelatine and 10-fold lower pharmacokinetic variability, with no liver-related adverse events reported in the seven-day MAD portion.
- R&D investment accelerated for lead program
- R&D spending rose $11.2 million year over year to $24.6 million in Q2, led by an $8.0 million increase for GlyphAllo as BUOY-1 and supporting studies advanced.
- Loss was materially affected by non-cash SBC
- The $62.6 million quarterly net loss included $36.0 million of non-cash G&A stock-based compensation, primarily from IPO-related award vesting and acceleration.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and operating expense rose sharply
- Q2 net loss widened to $62.6 million, or $1.78 per share, from $15.1 million a year earlier; total operating expenses increased $47.3 million to $65.8 million.
- Cash burn and eventual financing need remain
- Operating cash use increased $10.8 million year over year to $46.3 million for the first six months of 2026. Although liquidity was $427.3 million, management states it will need substantial additional capital in the future.
- Clinical execution remains the key valuation risk
- The filing highlights potential clinical-timing risk: BUOY-1 topline data are not expected until the first half of 2027, while the company reported an accumulated deficit of $202.1 million at June 30, 2026 and no product revenue.
- China sourcing and policy risk is highlighted
- Risk-factor disclosure flags potential supply-chain exposure from foreign providers and proposed BIOSECURE 2.0 restrictions; the company states it does business with companies in China, while its 2026 operating plan depends on external CROs and manufacturers.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.78
What they said about what is next.
No revenue or EPS guidance was provided. Management expects $427.3 million of cash, cash equivalents and investments at June 30, 2026 to fund operating expenses and capital expenditures into 2029; clinical timing targets include GlyphAllo driving-simulation data in 2H 2026 and BUOY-1 topline data in 1H 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · June 8, 2026
- Seaport Therapeutics reported a significant increase in net loss for Q1 2026, reaching $25.4 million compared to a loss of $13.1 million a year earlier. While revenues for the period remain nonexistent, R&D expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SPTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever